We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Prolexys Licenses the Prolexys Human Interactome Database to GlaxoSmithKline
News

Prolexys Licenses the Prolexys Human Interactome Database to GlaxoSmithKline

Prolexys Licenses the Prolexys Human Interactome Database to GlaxoSmithKline
News

Prolexys Licenses the Prolexys Human Interactome Database to GlaxoSmithKline

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Prolexys Licenses the Prolexys Human Interactome Database to GlaxoSmithKline "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Prolexys Pharmaceuticals, Inc. has announced that it has completed a non-exclusive license agreement with GlaxoSmithKline for the Prolexys Human Interactome Database.

This database contains over 258,000 human protein-protein interactions, representing approximately one half of all RefSeq entries.

The dataset was built from a wide range of human cell and tissue types using the Company's HyNet™ system, a highly automated high-throughput yeast 2-hybrid process.

This system is designed to give a strong preference to high confidence interactions and the quality of the data has been demonstrated in a variety of tests.

“This asset adds significant value to state-of-the-art pharmaceutical research programs in the areas of novel target identification, target validation, improved understanding of disease biology, and efficient choice of research direction,” said Dr. Sudhir Sahasrabudhe, Chief Scientific Officer of Prolexys.

Advertisement